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The phase III DATA study investigates the efficacy of adjuvant anastrozole (6 vs. 3 year) in postmenopausal women with breast
cancer previously treated with 2–3 years of tamoxifen. This planned side-study assessed patterns of care regarding detection
and treatment of osteopenia/osteoporosis, and trends in bone mineral density (BMD) during and after therapy. We registered
all BMD measurements and bisphosphonate-use. Time to osteopenia/osteoporosis was analysed by Kaplan Meier
methodology. For the trend in T-scores we used linear mixed models with random patients effects. Of 1860 eligible DATA
patients, 910 (48.9%) had a baseline BMD measurement. Among patients with a normal baseline BMD (n = 417), osteopenia
was observed in 53.5% and 55.4% in the 6- and 3-year group respectively (p = 0.18), during follow-up. Only two patients
(3-year group) developed osteoporosis. Of the patients with osteopenia at baseline (n = 408), 24.4% and 20.4% developed
osteoporosis respectively (p = 0.89). Three years after randomisation 18.3% and 18.2% used bisphosphonates in the 6- and
3-year groups respectively and 6 years after randomisation this was 23.7% and 20.9% respectively (p = 0.90) of which the
majority used oral bisphosphonates. The yearly mean BMD-change during anastrozole in the lumbar spine showed a T-score
decline of 0.075. After bisphosphonate addition the decline became less prominent (0.047 (p < 0.001)) and after anastrozole
cessation, while continuing bisphosphonates, the mean BMD yearly increased (0.047 (p < 0.001)). In conclusion, extended
anastrozole therapy was not associated with a higher incidence of osteoporosis. Anastrozole-use was associated with a BMD
decrease; however, the decline was modest and partially reversible after anastrozole cessation.
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Osteoporosis is estimated to affect 200 million women worldwide
and the proportion of osteoporosis increases with advancing
age - approximately in 3.3% for age 45–49, 6.4% for age 50–54,
13.5% for age 55–59, up to 50.3% in the highest age group of
85 years and above.1 In both Europe and the United States, 30%
of women have osteoporosis, and at the age of 50 roughly 40%
of post-menopausal women will experience an osteoporotic frac-
ture during their remaining life.2,3
A reduction of the bone mineral density (BMD) is a
well-known side effect of aromatase inhibitors (AI), which is
of substantial clinical concern in early breast cancer patients
for whom endocrine therapy is indicated, because they survive
for many years after treatment. As these women age, any early
decrease in BMD puts them at a clear disadvantage with an
increased fracture risk. In general, a 10–12% loss in BMD can
be compared to a 1 point drop in T-score, and an increase of
the fracture risk by 2.6 times.4 Hence maintenance of BMD
during endocrine therapy is important. Currently, very few data
are available on how the BMD develops during and after cessation
of (extended) endocrine therapy with aromatase inhibitors.5,6 The
DATA study investigated the efficacy of 6 vs. 3 years of adjuvant
anastrozole after a prior treatment with 2–3 years of tamoxifen in
postmenopausal women with hormone receptor positive early
breast cancer.7 We pre-planned a side study to evaluate patterns of
care considering bone health in these women, and the trend of
BMD over time during and after cessation of anastrozole treat-
ment. These research questions are addressed in the current report.
Methods
Study design
The DATA study (NCT00301457) is a prospective randomised
phase III study in which postmenopausal women with early
breast cancer were assigned to different durations of anastrozole
therapy (6 vs. 3 years) after 2 to 3 years of tamoxifen as adjuvant
endocrine therapy.7 The study included a total of 1860 eligible
postmenopausal women from June 2006 till August 2009. The
protocol of the bone-health side study was approved by the Med-
ical Ethical Committee of the Radboud University Nijmegen at
November 22, 2009.
Guidelines and definitions
In the DATA study it was advised to adhere to (inter)national
guidelines on the management of bone health, including lifestyle
recommendations. In 2008 the Dutch guidelines on osteoporosis
were updated, with more stringent recommendations on BMD
evaluations and (prophylactic) treatment with calcium, vitamin
D, and lifestyle advices on smoking, alcohol, and exercise. In
2012 the guideline recommended evaluating BMD every 2 years
and starting bisphosphonates from a T-score of −2.0 instead of
−2.5. BMD measurements were done by dual-energy X-ray
absorptiometry (DEXA) scans of the lumbar spine and/or total
hip. The BMD was considered normal when the measurement
was less than 1 standard deviation (SD) below the average value
for young healthy women (T-score >−1), osteopenia when
the BMD was between 1 and 2.5 SD below the average (T-score
between −1 and −2.5), and osteoporosis when the BMD was
more than 2.5 SD below the average (T-score <−2.5).8 Only
DEXA scans before appearance of a distant recurrence were
analysed.
Data collection
Data on bone health issues were collected by local data
managers in the 79 participating hospitals in the Nether-
lands, partly retrospectively and partly prospectively from
2 years before until 7 years after randomisation irrespective
of treatment arm. We registered the absolute BMD measure-
ments and the T score for both the total hip and lumbar
spine. Patient records were checked for the presence of risk
factors of reduced BMD at study entry. In addition, the use
of calcium, vitamin D supplements, and bisphosphonates
was collected. Finally, the date of bone fractures was
registered.
Study objectives
The primary study objective was to assess patterns of care
regarding prevention, detection and treatment of osteoporosis
in postmenopausal breast cancer patients without distant
recurrences who were treated with adjuvant anastrozole after
prior tamoxifen. Therefore, we evaluated the frequency
of BMD assessments, the follow-up assessments of BMD
depending on the result of the baseline scan, and the pre-
scription of bone protective medication, all related to the
duration of endocrine treatment (6 vs. 3 years anastrozole).
Moreover, we analysed the linear trend of the BMD mea-
surements over time during and after anastrozole therapy
and the effect of bone protective medication, and the number
of fractures.
What’s new?
Loss of bone mineral density (BMD) is a side effect of aromatase inhibitor treatment, a class of drugs that stops estrogen
production in postmenopausal women with breast cancer. Here the authors examined BMD loss during and after extended adjuvant
endocrine therapy, following a 2-3 year treatment with tamoxifen, subsequent aromatase inhibitor treatment was associated with
BMD decrease, but the decline was modest and partially reversible after treatment cessation. The authors concluded that extended
endocrine therapy was not associated with a higher incidence of osteoporosis.
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Figure S1 shows the patient selection for the performed ana-
lyses. The time from randomisation to first or second DEXA
scan and the time period to the prescription of bisphospho-
nates were analysed by the Kaplan Meier method, considering
distant recurrences or death a competing risk. The time
periods were censored at the date of last follow-up. The base-
line DEXA scan was defined as the last scan in the period
between 2 years before, and 1 year after randomisation. If the
event of interest (first DEXA scan, start bisphosphonates)
occurred before randomisation, it was set at day 1 after rando-
misation. For the analysis on the time to first DEXA scan, the
first scan reported could be a baseline scan or performed later
on. The number of scans in the 6- and 3-year arm were com-
pared to the Wilcoxon rank sum test.
Diagnosis of osteopenia and osteoporosis was based on the
lowest T-score available in either the hip or the lumbar spine.
Time to osteopenia or osteoporosis was censored at the last
Table 1. Baseline characteristics of all eligible randomised patients in the DATA study comparing 3 and 6 years of anastrozole after 2 to
3 years of tamoxifen (n = 1,860)
Total group 6 years anastrozole 3 years anastrozole
n = 1,860 (%) n = 931 (%) n = 929 (%)
Age (years) (median (IQR)) 58.1 (51.9; 64.8) 57.8 (51.5; 64.6)
<60 n (%) 1,063 (57.2) 531 (57.0) 532 (57.3)
≥60 n (%) 797 (42.8) 400 (43.0) 397 (42.7)
Duration of post menopause at randomisation
(years) n (%)
<5 805 (43.3) 392 (42.1) 413 (44.5)
5–10 242 (13.0) 116 (12.5) 126 (13.6)
10–20 345 (18.5) 181 (19.4) 164 (17.7)
>20 331 (17.8) 164 (17.6) 167 (18.0)
Unknown 137 (7.4) 78 (8.4) 59 (6.4)
BMI (kg/m2) n (%)
≤24.9 689 (37.0) 345 (37.1) 344 (37.0)
25.0–29.9 712 (38.3) 368 (39.5) 344 (37.0)
30.0–34.9 298 (16.0) 142 (15.3) 156 (16.8)
≥35.0 93 (5.0) 48 (5.2) 45 (4.8)
Unknown 68 (3.7) 28 (3.0) 40 (4.3)
Smoking n (%)
Current/previous smoker 943 (50.7) 465 (50.0) 478 (51.5)
Prior (neo) adjuvant chemotherapy n (%)
Yes 1,259 (67.7) 628 (67.5) 631 (67.9)
Prior Tamoxifen duration (years) n (%)
≤2.5 1,344 (72.3) 677 (72.7) 667 (71.8)
>2.5 516 (27.7) 254 (27.3) 262 (28.2)
History of bone fractures at baseline (%)1
Yes 106 (5.7) 65 (7.0) 41 (4.4)
Baseline BMD measurement (n (%))1
Not done 950 (51.1) 470 (50.5) 480 (51.7)
Done 910 (48.9) 461 (49.5) 449 (48.3)
Normal 417 (45.8) 201 (43.6) 216 (48.1)
Osteopenia 408 (44.8) 216 (46.9) 192 (42.8)
Osteoporosis 85 (9.3) 44 (9.5) 41 (9.1)
Actual treatment at baseline1
Vitamin D and/or Calcium (%)
Yes 445 (23.9) 241 (25.9) 204 (22.0)
Bisphosphonates
Yes 168 (9.0) 89 (9.6) 79 (8.5)
BMI: Body Mass Index, BMD: Bone Mineral Density.
1Baseline was considered −2 years before randomisation until 1 year after randomisation.
van Hellemond et al. 1327


















DEXA scan available for the patient when osteopenia or
osteoporosis was not detected.
For assessing the effect of anastrozole on BMD we used a lin-
ear mixed model for the T-score, separately analysed for the hip
and the lumbar spine. Dependency of measurements within the
same patient was modelled by a random factor for patient. The
time from anastrozole start to BMD measurement was included
as a continuous covariate with a linear time effect that changed
after stopping anastrozole. In addition, the linear effect of the time
since start of bisphosphonate was incorporated in the model. Re-
sidual plots were used to verify the model assumptions of homo-
geneity and normally distributed errors.
For each year of follow-up, the annual fracture rate was
calculated for patients being distant recurrence free and plotted
at the midpoint of the interval. Multiple fractures could be
reported in a single patient. A univariate Cox regression analysis
was used to identify risk factors for developing fractures. The
6- and 3-year treatment groups were compared for the incidence
of fractures starting after 3 years of anastrozole treatment because
until that time both groups received the same treatment by using
the log-rank test. All reported p-values are two-sided and a
p-value ≤ 0.05 was considered statistically significant. All analyses
were performed using SAS version 9.2.
Results
Patients
In the DATA study, 1860 patients were considered eligible. At
randomisation, the median age was 58.1 years (interquartile
range (IQR) 51.9–64.8) in the 6-year arm and 57.8 years (IQR
51.5–64.6) in the 3-year arm. Of these patients, 67.7% had
received (neo-) adjuvant chemotherapy, and 32.5% of patients
had node-negative disease. All patients had hormone receptor
positive disease and 2.6% HER2 positive disease. Table 1
shows the risk profile and prior history regarding BMD. The
baseline characteristics were well balanced.
BMD assessments
During 7 years of follow-up, the BMD was measured in
730 patients (78.0%) in the 6-year and in 650 (69.6%) in the
3-year arm (Fig. 1a). More measurements were performed in
Figure 1. (a) Time to first DEXA scan, related to duration of Anastrozole therapy (3 vs. 6 years). Time to the second DEXA scan if the baseline
scan showed a (b) normal BMD (c) osteopenia (d) osteoporosis. Overall, 30.2% of the patients had one BMD measurement, 20.3% had two
measurements, 13.7% had three measurements, 10.0% had four or more measurements, and in 25.8% of the patients no BMD measurement
was performed in the period from 2 years before randomisation until 7 years after randomisation.
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the 6-year treatment arm in comparison with the 3-year arm
(p < 0.001). The baseline characteristics of the patients with a
BMD measurement (n = 1,380) were comparable to the total
study population (n = 1,860; Table S1).
Follow-up assessments BMD after baseline scan
Overall, 910 (48.9%) patients had a baseline BMD measure-
ment, which indicated a normal BMD in 417 (45.8%) patients,
osteopenia in 408 (44.8%), and osteoporosis in 85 (9.3%). At
sixht year, after the baseline scan, a second DEXA scan was
performed in 60.6% of the patients in the 6-year and 54.4% in
the 3-year group if the baseline scan was normal (Fig. 1b), and
in 73.3% and 68.1% respectively if the baseline scan showed
osteopenia (Fig. 1c), and in respectively 76.4% and 62.6% if the
baseline scan showed osteoporosis (Fig. 1d).
If the baseline measurement showed a normal BMD, osteope-
nia was observed in the following 6 years in 53.5% of patients in
the 6-year group and in 55.4% of the 3-year group (p = 0.18),
while osteoporosis developed in only two patients in the 3-year
arm (Figs. 2a–2b). If the baseline measurements showed osteo-
penia, 24.4% developed osteoporosis in the 6-year group and
20.4% in the 3-year group (p = 0.89) within 6 years after baseline
measurement (Fig. 2c).
Of the 1,380 patients with at least one DEXA scan, 59.4%
in the 6-year arm vs. 67.4% in the 3-year arm had either
osteopenia or osteoporosis at 3 years after randomisation.
Six years after randomisation these percentages were 84.9%
and 86.3% for the 6- and 3-year arm respectively (p = 0.08).
Osteoporosis was diagnosed in 12.9% vs. 15.5% at 3 years
after randomisation and 25.1% vs. 27.4% 6 years after rando-
misation in the 6- and 3-year groups respectively (p = 0.24).
Prescription of bone protective medication
Three years after randomisation 18.3% and 18.2% used bispho-
sphonates in the 6- and 3-year groups respectively and 6 years
after randomisation this was 23.7% and 20.9% respectively
Figure 2. (a) Time to the development of osteopenia or osteoporosis if the DEXA scan at baseline showed a normal BMD. (b) Time to the
development of osteoporosis if the DEXA scan at baseline showed a normal BMD. (c) Time to the development of osteoporosis if the DEXA
scan at baseline showed osteopenia. At the beginning the lines remain horizontal because of the time interval between the baseline scan
and the second scan. The scan performed within 1 year after randomisation was by definition the baseline scan.
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(p = 0.90). Of the patients in whom bisphosphonates were pre-
scribed, the majority used oral bisphosphonates (59.3% alendro-
nate, 27.0% risedronate, 0.6% clodronate, 6.6% ibandronate)
and few used intravenous bisphosphonates (3.2% pamidronate,
2.7% zoledronate). Only 0.6% received denosumab.
BMD outcome
The annual change of the mean T-score in the hip and the
lumbar spine is shown for the average patient not treated with
bisphosphonates (Fig. 3a) and the average patient treated with
bisphosphonates (Fig. 3b).
Fractures
The annual incidence of fractures per treatment arm as of rando-
misation is shown in Figure 4. Fractures, as of 3 years after ran-
domization, occurred in 67 (7.9%) and 52 (6.1%) patients in the
6- and 3-year treatment arms, respectively (p = 0.85). We identi-
fied age above 60 years, a decreased BMD at baseline (osteope-
nia/osteoporosis), previous fractures, and a family history for
osteoporosis as risk factors for experiencing fractures.
Discussion
In this planned side-study of the phase III DATA study investi-
gating the efficacy of 6 vs. 3 years of adjuvant anastrozole after
2–3 year of tamoxifen in postmenopausal women with breast
cancer we assessed patterns of care regarding detection and treat-
ment of osteopenia/osteoporosis and linear trends over time in
BMD both during and after anastrozole therapy. Only 48.9% of
all eligible patients had a baseline BMD measurement. It showed
osteopenia in 44.4% and osteoporosis in 9.3% of them which is
comparable with the general population.9 Although subsequent
anastrozole use was associated with a BMD decrease, in patients
with a normal baseline BMD only two patients in the 3-year
arm developed osteoporosis, none in the 6-year arm. The BMD
decline was seen regardless of assigned treatment arm. Of the
patients with osteopenia at baseline, about a fifth developed sub-
sequent osteoporosis. Interestingly, the average yearly absolute
decrease in mean T-score during anastrozole therapy seemed
rather limited (−0.075 in the lumbar spine, −0.079 in the hip;
~1%). Bisphosphonate use partially compensated this effect in the
lumbar spine, but not in the hip. After cessation of anastrozole
and continuation of bisphosphonates, the T-score stabilised in the
hip, whereas it actually increased in the lumbar spine. The frac-
ture rate was quite low and during the 6-year observation period
not related to the assigned anastrozole treatment duration.
Healthy women experiencing natural menopause undergo an
accelerated, transient phase of bone loss of ~3% per year during
the first 1–2 years, slowing to ~1% annually thereafter.10 AI-
associated bone loss occurs at approximately twice the rate of
physiologic postmenopausal bone loss at an average of ~2% per
Figure 3. The annual change in mean T-score showing the effects of anastrozole and bisphosphonates on the hip and lumbar spine (a) in
patients not receiving bisphosphonates, (b) in patients in whom bisphosphonates were started during the use of anastrozole. This figure
shows the trend of the mean BMD in T-score for an average patient. In the linear mixed models with random effects, the development of the
BMD in the hip during anastrozole use over time showed a decrease of the mean T-score of −0.079 (95% CI −0.090 to −0.067). When
anastrozole was stopped the yearly decline was −0.024 (95% CI −0.47 to −0.001), which was a statistically significant change (p < 0.001)
(a). During anastrozole-use, the prescription of bisphosphonates failed to stop the decrease of the mean T-score (yearly decrease of −0.072
(95% CI −0.085 to −0.058)) (p-value for change = 0.21). When anastrozole was stopped and bisphosphonates were continued the T-score
stabilised (yearly decrease of −0.017 (95% CI −0.040 to 0.006)) which was a statistically significant change (p < 0.001) (b). The development
of the BMD in the lumbar spine during AI use over time showed a yearly decrease of the mean T-score of −0.075 (95% CI −0.089 to −0.060).
When anastrozole was stopped, the T-score stabilised to a yearly change of 0.019 (95% CI −0.009 to 0.048), which was a statistically
significant change (p < 0.001) (a). During anastrozole-use, the prescription of bisphosphonates resulted in a less steep decline of −0.047
(95% CI −0.064 to −0.031) per year (p-value for change <0.001), and when the AI was stopped the T-score increased yearly with 0.047 (95%
CI 0.018–0.075) (p-value for change <0.001) (b).
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year which continues throughout the duration of therapy.11,12 The
extent of AI-associated bone loss was studied in several trials. The
ATAC trial found significant BMD reductions in patients during
5 years of anastrozole treatment: −6.1% at lumbar spine and
−7.2% at the hip.12,13 Treatment with letrozole resulted in compa-
rable bone loss in the MA.17 trial: at 24 months showing a
significant additional decrease in total hip BMD (−3.6% vs. −0.7%;
p = 0.044) and lumbar spine BMD (−5.4% vs. 0.7%; p = 0.008).14
Also the ZO-FAST trial showed a median loss in lumbar spine
BMD of −5.4% after 5 years of letrozole treatment without bispho-
sphonate use (p < 0.0001).15 Decrease in BMD was apparently
lower in patients treated with exemestane in the Intergroup Exe-
mestane Study (IES), possibly related to its steroidal structure:
−1.0% (lumbar spine) and −0.8% (total hip) at 24 months.16 In
our study, we also observed a decline of ~1% per year.
Moreover, it is important to realise that premenopausal
women, who experience chemotherapy-induced ovarian function
failure and receive ovarian suppression, pass through a much
more distinct decrease in BMD within a short period of time
(up to −7.7% in the first year).17,18 The effect of ovarian suppres-
sion in combination with AIs is even worse, with reports of
up to −17.3% BMD loss within 3 years compared to baseline
(p < 0.0001).5,17,19
Hence, several prospective randomised studies observed nega-
tive consequences of AI-therapy on BMD in pre- and postmeno-
pausal women. However, only few data are available on how
BMD changes after adjuvant endocrine therapy is ended. In the
ABCSG-12 trial, patients receiving endocrine therapy alone
(i.e., goserelin plus tamoxifen or anastrozole) had a partial
BMD recovery 2 years after completing therapy, but their
BMD remained significantly lower than baseline BMD (mean
for lumbar spine −6.3%, p = 0.001).5 The ATAC trial also
showed a recovery at 2 years after completion of anastrozole
treatment (+4.0% at the lumbar spine and +0.5% at the hip).6
Our study is the first trial to specifically investigate bone health
during and after extended AI therapy after initial tamoxifen
treatment. Even though approximately half of the women with
a normal BMD developed osteopenia, we showed no clinically
relevant differences in the occurrence of osteopenia, osteopo-
rosis, or fractures between 6 and 3 years of anastrozole treat-
ment. Therefore for women with a normal BMD at the start of
AI therapy being postmenopausal at breast cancer diagnosis,
the time interval between DEXA scans can be longer than the
2 year currently advised in (inter)national guidelines.20
Moreover, we showed that after the start of anastrozole the
yearly decrease in absolute T-score was −0.079 and −0.075 in
the hip and lumbar spine respectively (absolute decrease of ~0.23
in T-score over a 3-year treatment and ~0.45 over a 6-year treat-
ment), which was partially compensated if bisphosphonates were
prescribed. Consequently, we consider a decreased BMD not as a
major reason for disregarding extended endocrine therapy. Sev-
eral trials demonstrated that treatment-induced bone loss could
be successfully prevented if bisphosphonates were started imme-
diately at the initiation of endocrine therapy not depending on
actual BMD.5,15,21,22 Yet, it remains unknown whether
upfront use of bisphosphonates also reduces the incidence of
fractures. More recently, denosumab was shown to increase
BMD and reduce fractures into a great extent.23 However, dis-
continuation of denosumab in patients with osteoporosis or
vertebral fractures is associated with a strong decrease in
BMD, exceeding the initial increase in BMD shown over a
period of 7–10 years, and an increased risk of vertebral
fractures.24–26 Therefore, denosumab should not be stopped in
these patients without considering alternative treatment.
When we compared the fracture rates of our study (6.1–7.9%)
with those of the ABCSG-18 trial, the NSABP B42, and the
IDEAL trial, all concerning postmenopausal breast cancer
patients receiving aromatase inhibitor treatment, these were
comparable.23,27,28 Only the fracture rate in the placebo arm
from the ABCSG-18 trial had a higher incidence of fractures
(9.6%). We believe this is possibly due to the fact that these
patients were not allowed to receive bisphosphonates which is
in contrast with both treatment arms in the DATA trial.
In our study, we identified an age above 60 years, osteo-
penia or osteoporosis at baseline, a history of fractures, and a
family history of osteoporosis as risk factors for experiencing
fractures during and after adjuvant anastrozole therapy.
These risk factors match with the factors implemented in the
WHO fracture risk assessment tool (FRAX®; http://www.
sheffield.ac.uk/FRAX/).29 Therefore we suggest that the man-
agement of bone health during adjuvant endocrine therapy
should be based on the baseline BMD measurement and the
presence of risk factors for developing fractures according
to FRAX®.
In our study anastrozole therapy was started after 2–3 years of
tamoxifen, which is known to counteract BMD loss and decreases
Figure 4. Annual fracture rate for the patients in the 6- vs. 3-year
anastrozole treatment group.The total number of fractures during the
7 years after randomisation was 217 (n = 118 in the 6-year group
and n = 99 in the 3-year group). Patients could have multiple
fractures.
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bone fracture rate in postmenopausal women.30 Therefore it can
be questioned into which extend our results are influenced by the
positive effect of tamoxifen on bone health. A sub-study of the
BIG 1–98 trial, comparing four 5-year regimens of endocrine ther-
apy, looked at the effect of each regimen on BMD.31 They found
that the sequenced treatment of tamoxifen followed by letrozole
had the worst effect on BMD and that letrozole followed by
tamoxifen appeared to preserve BMD. They hypothesized that the
interruption of tamoxifen combined with the rapid fall in oestro-
gen levels induced by letrozole promotes an accelerated bone turn-
over and loss of BMD following the switch as was confirmed by
bone turnover biomarkers.31
Limitations
Our study has several limitations. The evaluation of BMD was
not standardised but left at the discretion of the treating physician.
The reason not to perform a DEXA scan at baseline in more
than half of the women and no DEXA scan at all in a quarter
of the patients is unknown. Moreover, the DEXA scans were
not standardised since patients were treated in different hospi-
tals. Selection based on patient characteristics (e.g. fractures,
and familial osteoporosis) could not be ruled out. In our study,
we report on the linear change of BMD over time during the
use of anastrozole with or without bisphosphonates. In our
model we could not evaluate if the BMD decrease over time
was more profound in the early years of menopause and/or
directly after the start of anastrozole because the minimum
interval between DEXA scans was 1 year and scans were not
performed at set times.
Conclusion
This is one of the first studies reporting on bone health during
and after extended endocrine therapy. We conclude from our
study, that although subsequent anastrozole use was associ-
ated with a BMD decrease, extended endocrine therapy was
not associated with a higher incidence of osteoporosis or frac-
tures. Nowadays, an increasing number of postmenopausal
women are treated with bisphosphonates in the adjuvant set-
ting, which also showed to compensate the negative effect of
AIs on BMD. Therefore, with the availability of bisphospho-
nates, we believe bone health should not be a major argument
in disregarding extended endocrine therapy.
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